Management of Purulent Cellulitis

Definition & Epidemiology

Purulent cellulitis is identified by the presence of purulent drainage or exudate without a drainable abscess. 2
The predominant pathogen in this phenotype is community‑acquired MRSA, making empiric streptococcal coverage generally unnecessary. 2

Clindamycin 300–450 mg orally three times daily for 5 days is the preferred first‑line regimen because it provides coverage against both MRSA and β‑hemolytic streptococci. 1
Clindamycin carries a higher risk of Clostridioides difficile infection compared with other oral agents. 1
Trimethoprim‑sulfamethoxazole (TMP‑SMX) 1–2 double‑strength tablets twice daily covers MRSA only and must be combined with a β‑lactam (e.g., amoxicillin) to ensure streptococcal coverage. 1
Doxycycline 100 mg twice daily also covers MRSA only and requires addition of a β‑lactam for streptococcal activity. 1
Minocycline (loading dose 200 mg, then 100 mg twice daily) provides MRSA coverage alone. 1
Linezolid 600 mg twice daily is an effective MRSA agent but is more costly than other oral options. 1

A 5‑day oral course is sufficient for most patients who show clinical improvement. 2
Therapy should be extended only if there is no improvement by day 5. 2
Patients should be re‑evaluated at 48–72 hours after starting therapy to confirm reduction in erythema, swelling, and tenderness. 3

Systemic toxicity (fever, hypotension, altered mental status) or fulfillment of SIRS criteria. 1, 2
Rapid progression or worsening despite appropriate oral antibiotics. 1
Complicated skin‑and‑soft‑tissue infection involving multiple sites, deep tissue, or surgical/traumatic wounds. 2
Presence of significant comorbidities or immunosuppression (e.g., diabetes, HIV/AIDS, malignancy). 1
Extremes of age. 1
Abscesses located in areas that are difficult to drain completely (face, hand, genitalia). 1

Vancomycin 15–20 mg/kg IV every 8–12 hours – first‑line agent. 1, 4
Linezolid 600 mg IV or PO twice daily – alternative to vancomycin. 1, 4
Daptomycin 4 mg/kg IV once daily – another effective option. 1, 4
Telavancin 10 mg/kg IV once daily – can be considered when other agents are unsuitable. 1

Do not use TMP‑SMX or doxycycline as monotherapy when streptococcal co‑infection is possible; they must be combined with a β‑lactam. 1
Do not add rifampin as adjunctive therapy; it offers no clinical benefit and promotes resistance. 1
Do not prescribe antibiotics routinely after incision & drainage of a simple abscess in immunocompetent patients without surrounding cellulitis. 1
Do not extend antibiotic courses beyond 5 days in patients who are clinically improving. 2

TMP‑SMX is contraindicated in the third trimester of pregnancy and in infants younger than 2 months. 1
Tetracyclines (doxycycline, minocycline) are not recommended for children younger than 8 years and are pregnancy category D. 1
Inducible clindamycin resistance: its clinical relevance is unclear for mild infections, but it should preclude clindamycin use in serious infections. 1
Local clindamycin resistance >10 %: alternative agents should be selected. 3

Elevating the affected limb helps drain edema and inflammatory mediators. 3
Addressing predisposing factors (e.g., tinea pedis, venous insufficiency, lymphedema) reduces the risk of recurrence. 2
Surgical consultation is warranted for suspected deep‑space infection, necrotizing fasciitis, or failure to respond to medical therapy. 4